Notice of Public Hearing

Pursuant to subsection E of § 54.1-3443, the Board of Pharmacy is giving notice of a public hearing to consider placement of chemical substances in Schedule I of the Drug Control Act and to consider removal of chemical substances in Schedule IV. The public hearing will be conducted at 9:05 a.m. on March 30, 2023. Instructions will be included in the agenda for the board meeting, also on March 30th. Public comment may also be submitted electronically or in writing prior to September 6th to Caroline Juran, Executive Director of the Board of Pharmacy to caroline.juran@dhp.virginia.gov.

Pursuant to article § 54.1-3443(E), the following drugs will be placed in Schedule I to conform with federal scheduling actions taken from July 7, 2022 to February 3, 2023:

1. N-methyl-1-(thiophen-2-yl)propan-2-amine (other name:  methiopropamine)
2. N -phenyl- N′-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate (other name:  mesocarb)
3. 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol (other name:  zipeprol)
4. 7-[(10,11-dihydro-5 H -dibenzo[ a,d]cyclohepten-5-yl)amino]heptanoic acid (other name:  amineptine)

Pursuant to article § 54.1-3443(E), the following drug will be removed from Schedule IV to conform with federal scheduling actions taken from July 7, 2022 to February 3, 2023:

1. Fenfluramine